HIGHLIGHTS
- who: Xue-Gang Yang from the Foundation (IRCCS), Italy have published the Article: Efficacy and safety of transarterial chemoembolization combining sorafenib with or without immune checkpoint inhibitors in previously treated patients with advanced hepatocellular carcinoma: A propensity score matching analysis, in the Journal: (JOURNAL) of 31/Dec/2020
- what: These results indicated that the TACE combined with sorafenib and ICI regimen might be a superior treatment option in patients with BCLC C stage HCC who previously received locoregional treatment, which might be due to the following reasons: 1) TACE can lead to tumor necrosis after . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.